{
  "success": true,
  "sourceFile": "input\\Alexion_NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gpt-5.1",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "SSCR",
        "description": "All participants who signed informed consent and underwent any screening assessments",
        "criteria": "All participants who provided informed consent and had any screening procedure performed"
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "ENR",
        "description": "All participants who were enrolled into the study (typically on Day -7) according to the protocol",
        "criteria": "All participants who met eligibility criteria and were formally enrolled in the study"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "description": "Primary efficacy analysis population, generally aligned with the ICH E9 intent‑to‑treat principle",
        "criteria": "All enrolled participants who received at least 1 dose of ALXN1840 and have sufficient intake/output data to contribute to copper/molybdenum balance assessments"
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "description": "Subset of the Full Analysis Set without major protocol deviations that could affect primary efficacy evaluation; used for sensitivity analyses when the PP Set has at least 3 participants",
        "criteria": "Participants in the Full Analysis Set who have no major protocol deviations judged to impact the assessment of copper/molybdenum balance, and who complete required baseline and on‑treatment collection periods"
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "description": "Population used for all safety analyses including adverse events, laboratory tests, vital signs, ECGs, and exposure",
        "criteria": "All participants who received at least 1 dose of ALXN1840"
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "populationType": "PK",
        "instanceType": "AnalysisPopulation",
        "label": "PKAS",
        "description": "Population used for PK concentration and parameter analyses of ALXN1840 and molybdenum",
        "criteria": "All participants who received at least 1 dose of ALXN1840 and have at least one evaluable PK sample (e.g. on Days 1, 25, 29, or 39) without significant PK-related protocol deviations"
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "populationType": "PD",
        "instanceType": "AnalysisPopulation",
        "label": "PDAS",
        "description": "Population used for PD analyses related to copper disposition and PD biomarkers (e.g., plasma copper measures)",
        "criteria": "All participants who received at least 1 dose of ALXN1840 and have at least one evaluable PD measurement as per protocol (e.g. during intake/output collection periods) and no major PD-related protocol deviations"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age in years at reference date (typically date of informed consent or first dose, per SAP Appendix 9.2.2 on age and dates)"
      },
      {
        "id": "char_2",
        "name": "Sex",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Sex of participant as recorded on CRF (e.g. male, female)"
      },
      {
        "id": "char_3",
        "name": "Race",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Race as collected on demographics CRF (e.g. White, Black or African American, Asian, etc.)"
      },
      {
        "id": "char_4",
        "name": "Ethnicity",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Ethnicity as collected on demographics CRF (e.g. Hispanic or Latino, Not Hispanic or Latino)"
      },
      {
        "id": "char_5",
        "name": "Body Mass Index",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Body mass index calculated from height and weight at baseline, per SAP Appendix 9.2.5"
      },
      {
        "id": "char_6",
        "name": "Baseline Disease Characteristics – Wilson Disease History",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Wilson Disease (WD) history including age at diagnosis, disease duration, clinical presentation, and relevant disease status at baseline, as summarized in Section 7.1.3.2 and 7.1.3.3"
      },
      {
        "id": "char_7",
        "name": "Baseline Copper Balance",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Mean daily copper balance during pretreatment baseline (Days -4 through -1), measured as intake (food and drink) minus output (feces and urine)"
      },
      {
        "id": "char_8",
        "name": "Baseline Molybdenum Balance",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Mean daily molybdenum balance during pretreatment baseline (Days -4 through -1), analogous to copper balance"
      },
      {
        "id": "char_9",
        "name": "Baseline Copper Intake",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Total daily copper intake from food, drink, and study drug during the baseline collection period (Days -4 through -1)"
      },
      {
        "id": "char_10",
        "name": "Baseline Copper Output – Urine",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Daily urinary copper excretion during the pretreatment baseline period"
      },
      {
        "id": "char_11",
        "name": "Baseline Copper Output – Feces",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Daily fecal copper excretion during the pretreatment baseline period"
      },
      {
        "id": "char_12",
        "name": "Baseline Molybdenum Intake",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Total daily molybdenum intake from food, drink, and study drug during the baseline collection period"
      },
      {
        "id": "char_13",
        "name": "Baseline Molybdenum Output – Urine",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Daily urinary molybdenum excretion during the pretreatment baseline period"
      },
      {
        "id": "char_14",
        "name": "Baseline Molybdenum Output – Feces",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Daily fecal molybdenum excretion during the pretreatment baseline period"
      },
      {
        "id": "char_15",
        "name": "Baseline Plasma Copper Measures",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline plasma copper-related measures such as total copper and labile bound copper (LBC), as part of disease characteristics/PD profile"
      },
      {
        "id": "char_16",
        "name": "Baseline Plasma Molybdenum",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline plasma total molybdenum concentration"
      },
      {
        "id": "char_17",
        "name": "Medical and Surgical History",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Relevant prior medical and surgical history including comorbidities related to WD and other conditions (Section 7.1.3.3)"
      },
      {
        "id": "char_18",
        "name": "Prior WD Therapies",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "History of prior and ongoing therapies for Wilson Disease (e.g., penicillamine, trientine, zinc, prior ALXN1840), including duration >28 days vs ≤28 days used to define Cohort 1 (treatment-experienced) and Cohort 2 (treatment-naïve)"
      },
      {
        "id": "char_19",
        "name": "Prior and Concomitant Medications/Therapies",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "All prior and concomitant medications and therapies summarized by Anatomical Therapeutic Chemical (ATC) class and preferred name, including those used to treat WD as noted in Section 7.1.4 and Appendix 9.2.7"
      },
      {
        "id": "char_20",
        "name": "Baseline Laboratory Assessments",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline clinical laboratory parameters (e.g., liver enzymes ALT, AST, GGT; INR; other safety labs) used to describe disease status and safety profile at baseline"
      },
      {
        "id": "char_21",
        "name": "Baseline Vital Signs",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Vital signs at baseline (e.g., blood pressure, heart rate, respiratory rate, body temperature), summarized per Section 7.3.3.2"
      },
      {
        "id": "char_22",
        "name": "Baseline ECG Parameters",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline electrocardiogram parameters (e.g., QT, QTc, QTcF) summarized per Section 7.3.3.4"
      },
      {
        "id": "char_23",
        "name": "Cohort (Treatment-experienced vs Treatment-naïve)",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Cohort classification based on prior WD therapy exposure: Cohort 1 (treatment experienced, >28 days of WD therapy) vs Cohort 2 (treatment naïve, ≤28 days of WD therapy)"
      }
    ],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 23
    }
  }
}